Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI) : a randomised, double-blind, placebo-controlled trial
- Submitting institution
-
University of Bristol
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 220859881
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(19)32981-2
- Title of journal
- The Lancet
- Article number
- -
- First page
- 294
- Volume
- 395
- Issue
- 10220
- ISSN
- 0140-6736
- Open access status
- Compliant
- Month of publication
- January
- Year of publication
- 2020
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
49
- Research group(s)
-
A - Cardiovascular Science
- Citation count
- 28
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a. The author made a substantial contribution to the conception and design of the study; and to the organisation of the conduct of the study.
b. The author helped draft the output and critique it for important intellectual content.
- Non-English
- No
- English abstract
- -
